PBM Reform Dates and Contract Changes: The Headline Does Not Rewrite the Contract

PBM reform effective dates depend on which contracts you mean: the 2026 law sets different clocks for Medicare Part D and commercial group plans. An employee handling rebates, contractual rates or sponsor reports needs more than a reform announcement. The agreement identifies what the PBM promised. The reconciliation shows what it actually counted, retained and paid. That is where a promise of full pass-through becomes a question about real money.

When Do PBM Reform Contract Changes Take Effect?

The Consolidated Appropriations Act, 2026 became law on February 3, 2026, with separate dates for reporting, compensation and pharmacy contracts. Its calendar reaches into earlier transactions as well as future agreements, because some reports look back at the previous plan year.

• Plan year 2027: Part D sponsors and Medicare Advantage plans with drug coverage must report specified pharmacy incentive payments and fees that they do not otherwise report.
• Plan year 2028: The Centers for Medicare & Medicaid Services must publish its essential retail pharmacy list, and sponsors must submit the pharmacy-affiliation information used for that list.
• Plan years beginning January 1, 2028 or later: Part D sponsor-PBM written agreements must carry the new compensation requirements, including requirements for relevant affiliates.
• July 1, 2028: The annual PBM report to the Part D sponsor and the government begins, covering the previous plan year.
• The first Monday in April 2028: The government must establish reasonable and relevant pharmacy-contract standards. Those standards apply to plan years beginning January 1, 2029.
• Covered commercial group plans: For plan years beginning on or after 30 months after enactment, the new reporting and rebate rules apply to contracts signed, renewed or extended on or after that trigger. For a calendar-year plan subject to that trigger, the plan-year date is January 1, 2029.

The commercial pass-through rule leaves an existing contract’s term in place if the contract is in effect when the rule starts. It reaches renewals or extensions entered into on or after that date. For an employee preparing new terms, the plan year and renewal history belong beside the payment promises.

What the Commercial PBM Contract Must Show

Once the new commercial pass-through rule applies to a contract, the PBM must remit rebates, fees, alternative discounts and other payments it receives from covered entities for the plan’s drug use or spending. The law preserves reasonable payments for bona fide services through transparent, quantifiable fees. The manufacturer payment, the PBM’s service compensation and the pharmacy’s reimbursement therefore remain separate parts of the accounting.

The remittance runs quarterly, no later than 90 days after the quarter ends. Rebate aggregators and applicable group purchasing organizations have an upstream deadline of 45 days after quarter-end to remit rebates to the PBM. Those deadlines connect the entity collecting the money with the entity responsible for passing it to the plan.

Reports must arrive at least every six months, or quarterly at the plan’s request on the same terms and cost, in plain language and machine-readable form. Qualifying large self-funded plans receive drug-level detail, including the plan’s contracted payment, pharmacy compensation and the difference. Qualifying large insured plans can elect that fuller reporting.

The detailed reporting also reaches explanations for certain formulary placements and benefit designs that steer prescriptions toward affiliated pharmacies. For someone inside the business, the useful comparison is between those explanations and the contracts and payments behind them.

The plan can audit rebate records at least once per plan year, including manufacturer and aggregator contracts under confidentiality restrictions. The plan’s responsible fiduciary chooses the auditor, and the PBM cannot pay that auditor.

Commercial reporting exposes spread by putting the plan charge beside pharmacy compensation. The pass-through rule addresses payments received from other entities. And the recipient of a rebate matters: a discount delivered to the plan after dispensing does not itself reduce the price used to calculate a patient’s coinsurance at the counter.

What Does 100 Percent Pass-Through Cover?

A full pass-through promise covers the money included in the agreement’s definition. Minnesota’s Caremark agreement promises all defined rebates while excluding certain mail and specialty purchasing discounts and specialty service revenue. The percentage tells only part of the story. The exclusions decide which money gets counted in the first place.

A Caremark agreement in Iredell County’s public contract packet includes relevant affiliate and group-purchasing-organization formulary receipts, with separate exclusions for manufacturer services and affiliated-pharmacy purchasing discounts. The Office of Personnel Management’s updated federal employee and postal health-benefit framework takes a broader approach, making the administrative fee the PBM’s sole profit source under the letter and requiring broader manufacturer-payment pass-through. These instruments make the contract question concrete: which recipient, which payment category, which claims and which exclusions?

We care about what survives the final reconciliation, not how impressive the percentage looks before the exclusions. A minimum rebate commitment can depend on eligible claims, excluded products, formulary conditions and permitted offsets. The manufacturer receipt and the sponsor’s final payment show how those definitions worked in practice.

Part D Delinking and Pharmacy Access Have Their Own Terms

Part D delinking ties service compensation to an actual, itemized service at fair market value, paid as a flat dollar amount. The future definition bars tying that fee to drug-price benchmarks, rebate amounts, formulary placement or referral and business volume. The law also provides for qualifying sponsor incentives and fully passed-through manufacturer concessions, and preserves specified pharmacy ingredient reimbursement and flat dispensing fees.

For an employee preparing a service agreement, the work performed and the basis for the fee matter together. Renaming a payment does not explain either one. The statute also calls for transparent definitions and exclusions for contractual pricing commitments, and a wholesale-acquisition-cost equivalent when a different pricing benchmark supports the commitment.

Pharmacy access follows the separate calendar above. The law requires a Part D sponsor to admit a pharmacy that meets the plan’s standard contract terms, with the new reasonable-and-relevant standards governing the later plan years. Its essential retail pharmacy definition combines an independence requirement with the absence of another retail pharmacy within ten miles in rural areas, two miles in suburban areas or one mile in urban areas, as determined by the government.

CMS’s September request for information seeks input on pharmacy contracting standards. Its October 20, 2026 rulemaking document proposes implementation of the PBM accountability provisions.

A separate pharmacy-concession rule already changed Part D’s negotiated price for 2024 to the pharmacy’s lowest possible reimbursement, including pharmacy concessions. Annual reporting still accounts for the difference between that price and final pharmacy reimbursement. An insider working through the newer compensation changes may therefore already be reconciling concessions that moved into the initial price.

Labor Department Disclosures and FTC Settlements Change Different Things

The Labor Department’s January 30, 2026 proposal addresses compensation disclosure for PBMs and affiliated brokers and consultants serving self-insured group health plans covered by the Employee Retirement Income Security Act. It proposes advance disclosure of expected compensation, followed by reports of actual receipts every six months. Its categories include manufacturer payments, spread, copay clawbacks and price-protection arrangements.

The proposal would require an explanation when a compensation category exceeds its corresponding quarterly estimate by 5% or more, or a lower threshold agreed in writing. The proposed text applies to plan years beginning on or after July 1, 2026, with effectiveness tied to publication of a final rule.

The Federal Trade Commission’s February Express Scripts notice and August Caremark and Zinc notice describe proposed settlements with those companies. Their proposed standard offerings include point-of-sale rebate benefits and the elimination of spread pricing and predetermined rebate commitments. They also permit certain sponsor-requested alternatives. In its June 12, 2026 action in the Optum case, the FTC paused the case to consider a proposed settlement.

A New PBM Model Still Needs a Client Agreement

Evernorth’s October 2025 announcement placed Cigna fully insured adoption of its new model in 2027 and standard availability to all Evernorth pharmacy-benefit clients in 2028. Optum’s model announcement separately committed to full manufacturer rebate pass-through by January 1, 2028.

The client amendment answers the next question: what did this sponsor actually accept, and when? The revised fee schedule, rebate-commitment exclusions and first reconciliation under those terms show how the announcement reached the account. We follow that change through to the money.

What the Reconciliation Can Reveal

Cases involving government drug spending show why a contract calendar needs the accounting beside it. The decisive adjustment can sit in another business’s reconciliation, a service-fee classification or a disputed rebate receipt.

Caremark’s Offset Crossed From Part D to Commercial Business

In a whistleblower case brought by an Aetna Medicare actuary, the court’s June 2025 findings against Caremark examined contractual generic effective rates combining commercial and Part D purchases at Walgreens and Rite Aid. Higher Part D payments relative to the contractual rate reduced Caremark’s commercial reconciliation obligation. The court treated those offsets as reportable price concessions even though no separate refund check returned the money.

The court’s opinion identifies reconciliation workbooks, an internal pricing presentation and sponsor-reporting attestations. It also explains that a point-of-sale audit excluded direct and indirect remuneration. The adjustment that mattered sat beyond the transaction that audit examined. For someone handling contractual rates, that is a concrete reason to connect the pharmacy payment with the later offset and the government report.

Elixir’s Alleged Rebate Retention Became a Service Fee

The government’s Elixir settlement agreement alleged that Elixir Insurance Company’s annual Part D reports excluded retained manufacturer rebates by classifying them as bona fide service fees. The agreement described retention without the manufacturers’ knowledge and fees that failed the governing definition. The alleged classification changed Part D reconciliation.

The whistleblower’s complaint also challenged the basis for valuing the supposed services. It alleged that the companies manufactured the supporting paperwork:

The government’s account ties together the manufacturer agreement, remittance, amount retained and sponsor reporting. That is the useful comparison when an insider sees money move into a different revenue category.

Compass Rose Put the Rebate Receipt Beside the Rebate Commitment

OPM’s inspector general examined Express Scripts-administered pharmacy operations for the Compass Rose federal employee health plan in its November 2024 audit. The audit questioned retail discounts, transaction credits, inventory discounts and affiliate-retained rebates. The carrier disputed parts of the contract interpretation.

For Ascent, the audit compared rebates collected with amounts passed through and an offset for payments made under the rebate commitment. It reported a credit or wire of the questioned rebate principal while recommending further confirmation.

Across these examples, the connection is the same: what the agreement required, what the accounting did and what reached the government-funded plan or its reports. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. We work with insiders to connect the promise, the payment and the decisions behind the reporting.

When You Know What Changed in the Account

If you work in PBM finance, plan contracting or pharmacy operations and know where the money reported falls short of the contract promise, speak with our whistleblower experts about that gap. We build the case with you around the agreement, reconciliation and government payment, and bring in PBM fraud whistleblower lawyers who understand rebate and contracted-rate disputes. We stay beside you as your partners through the case.